Выбор редакции

Bind and Amgen complete research program

  • Citing results that were not compelling enough to proceed, Bind Therapeutics (BIND -3.4%) and Amgen (AMGN +0.6%) notify each other that they will not be exercising their options to develop an Accurin incorporating the Amgen therapeutic payload. 
  • The collaboration began in January 2013 with the goal of developing a nanomedicine for treating solid cancer tumors based on Bind's platform for targeted and programmable nanomedicines and Amgen's undisclosed proprietary cancer compound. 
  • Bind CEO Scott Minick says that his company will proceed undeterred with its collaborations with AstraZeneca (AZN +2%), Roche (OTCQX:RHHBY -0.6%) and Pfizer (PFE +1%). 
Post your comment!